LIPIDRESCUE
Live / Applied — Fourth extension granted (statement of use) (as of 05 Sept 2025)
What this means for you
Not registered yet, but its 07 Jul 2022 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97492223
- Mark type
- Stylized text
- Filed
- 07 Jul 2022
- Published for opposition
- 29 Aug 2023
- Attorney of record
- Hillary Maynard
Goods and services
- Class 005 — Pharmaceuticals: Medical kits consisting primarily of a pharmaceutical preparation in the nature of a lipid emulsion sold inside of a bag, and also including a medical syringe for administering the lipid emulsion, all for use in treating anesthetic and drug toxicity; Medical kits consisting primarily of a pharmaceutical preparation in the nature of a lipid emulsion sold inside of a bag, and also including a medical syringe for administering the lipid emulsion, all for use in resuscitating patients; Medical kits consisting primarily of a pharmaceutical preparation in the nature of a lipid emulsion sold inside of a bag, and also including a medical syringe for administering the lipid emulsion, all for use in treating cardiac arrest due to ischemia and cardiac failure; syringes that are used for administering lipid emulsions in the nature of syringes sold filled with a pharmaceutical, namely, a lipid emulsion for use in treating anesthetic and drug toxicity, treating neurological toxicity, treating cardiac arrest due to ischemia, treating cardiac failure, treating cardiac toxicity, and for resuscitating patients
- Class 044 — Medical, beauty and agricultural services: Medical services, namely, treating anesthetic toxicity, treating drug overdoses and poisoning, resuscitating patients suffering from the toxic side effects caused by anesthetics and unknown substances, treating cardiac toxins, administering lipid emulsions and other lipid containing substances to patients, and administering lipid emulsions to treat cardiac arrest due to ischemia, cardiac failure, and cardiac toxicity
Owner
- ResQ Pharma, Inc., Chicago, IL, US
- ResQ Pharma, Inc., Chicago, IL, US
Prior registrations
Prosecution history
- 29 Jan 2026 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 05 Sept 2025 — SOU EXTENSION 4 GRANTED
- 05 Sept 2025 — SOU EXTENSION 4 FILED
- 05 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 18 Apr 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Apr 2025 — SOU EXTENSION 3 GRANTED
- 17 Apr 2025 — SOU EXTENSION 3 FILED
- 17 Apr 2025 — SOU TEAS EXTENSION RECEIVED
- 17 Oct 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 17 Oct 2024 — SOU EXTENSION 2 GRANTED
- 17 Oct 2024 — SOU EXTENSION 2 FILED
- 17 Oct 2024 — SOU TEAS EXTENSION RECEIVED
- 23 Mar 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 22 Mar 2024 — SOU EXTENSION 1 GRANTED